Form
SCHEDULE 13D/A
Active or control-oriented beneficial ownership filing.
BIOS Fund II, LP - 22 Dec 2025 SCHEDULE 13D/A Report for IN8BIO, INC. Common Stock, par value $0.0001 per share (INAB)
- Filing manager
- BIOS Fund II, LP
- Reporting owner
- BIOS Capital Management, LP
- Beneficially owned shares
- 391,357 shares
- Large-stake signal
-
Ownership
4%Beneficial ownership of this reported class.
Shares
391,357 sharesShares beneficially owned as disclosed.
Event date
22 Dec 2025Date tied to the ownership event or amendment.
Accepted by SEC
29 Dec 2025EDGAR acceptance date.
How to read this large-stake filing
- Schedule 13D/G filings focus on beneficial ownership stakes, not a full portfolio.
- Compare this filing with the holder history and issuer page before treating the percentage as a current position.
- Use amendments to understand whether the disclosed stake increased, decreased, or changed reporting status.
- Class ownership
- 4%
- Symbol
- INAB
- Shares outstanding
- 9,783,925 shares
- SEC form
- SCHEDULE 13D/A
- Accepted by SEC
- 29 Dec 2025, 16:00:52 UTC
- Event date
- 22 Dec 2025
- Prior SEC filing
- 08 May 2025
- Source filing
- View source filing
Ownership signal
CIK-linked ownership evidence from parsed SEC filings.
2 signals
Subject security
Names, identifiers, and filing context for this profile.
2 source fields
Source evidence
Original filing metadata and source links for verification.
5 source fields
Key filing fact
BIOS Fund II, LP disclosed 4% ownership in IN8BIO, INC. Common Stock, par value $0.0001 per share (INAB) on 22 Dec 2025.
Key facts
- BIOS Fund II, LP filed SCHEDULE 13D/A for IN8BIO, INC. Common Stock, par value $0.0001 per share (INAB).
- Disclosed ownership: 4%.
- Date of event: 22 Dec 2025.
Change
- Previous schedule filing date: 08 May 2025.
- Current filing was accepted on 29 Dec 2025, 16:00.
Research use
- This page turns one Schedule 13D/G filing into a quick large-stake read before the raw reporting-person rows.
- Use the linked SEC filing as the source of truth for ownership percentages, shares, and reporting-party details.
Evidence
Backed by Schedule 13D/13G
View source filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting persons
Disclosed reporting parties (19)
Names, ownership percentages, voting power, signatures, titles, and CIKs as disclosed in this Schedule 13D/G filing.
| Name | Ownership | Shares owned | Sole voting power | Shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| BIOS Fund II, LP | 0.2% | 19,147 | 0 | 19,147 | /s/ John Fucci | John Fucci/Attorney-in-Fact | 0001714576 |
| BIOS Fund II QP, LP | 0.6% | 62,554 | 0 | 62,554 | /s/ John Fucci | John Fucci/Attorney-in-Fact | 0001716869 |
| BIOS Fund II NT, LP | 0.1% | 8,373 | 0 | 8,373 | /s/ John Fucci | John Fucci/Attorney-in-Fact | 0001728851 |
| BIOS Incysus Co-Invest I, LP | 0.3% | 33,247 | 0 | 33,247 | /s/ John Fucci | John Fucci/Attorney-in-Fact | 0001740029 |
| BIOS Fund III, LP | 0.2% | 19,024 | 0 | 19,024 | /s/ John Fucci | John Fucci/Attorney-in-Fact | 0001791917 |
| BIOS Fund III QP, LP | 1.3% | 124,253 | 0 | 124,253 | /s/ John Fucci | John Fucci/Attorney-in-Fact | 0001791916 |
| BIOS Fund III NT, LP | 0.2% | 20,066 | 0 | 20,066 | /s/ John Fucci | John Fucci/Attorney-in-Fact | 0001791910 |
| Bios Clinical Opportunity Fund, LP | 1.1% | 104,693 | 0 | 104,693 | /s/ John Fucci | John Fucci/Attorney-in-Fact | 0001988639 |
| BP Directors, LP | 0% | 0 | 0 | 0 | /s/ John Fucci | John Fucci/Attorney-in-Fact | 0001813311 |
| Bios Equity Partners, LP | 0% | 0 | 0 | 0 | /s/ John Fucci | John Fucci/Attorney-in-Fact | 0001813314 |
| Bios Equity Partners II, LP | 1.3% | 123,321 | 0 | 123,321 | /s/ John Fucci | John Fucci/Attorney-in-Fact | 0001813313 |
| BIOS Equity Partners III, LP | 1.7% | 163,343 | 0 | 163,343 | /s/ John Fucci | John Fucci/Attorney-in-Fact | 0001831976 |
| Bios Equity COF, LP | 1.1% | 104,693 | 0 | 104,693 | /s/ John Fucci | John Fucci/Attorney-in-Fact | 0002000747 |
| Cavu Management, LP | 2.9% | 286,664 | 0 | 286,664 | /s/ John Fucci | John Fucci/Attorney-in-Fact | 0001813270 |
| BIOS Capital Management, LP | 4% | 391,357 | 0 | 391,357 | /s/ John Fucci | John Fucci/Attorney-in-Fact | 0001813845 |
| Cavu Advisors, LLC | 2.9% | 286,664 | 0 | 286,664 | /s/ John Fucci | John Fucci/Attorney-in-Fact | 0001813310 |
| BIOS Advisors GP, LLC | 4% | 391,357 | 0 | 391,357 | /s/ John Fucci | John Fucci/Attorney-in-Fact | 0001813844 |
| Kreis Leslie W. | 2.9% | 286,664 | 0 | 286,664 | /s/ John Fucci | John Fucci, as Attorney-in-Fact for Leslie W. Kreis, Jr. | 0001813316 |
| Fletcher Aaron G.L. | 4% | 391,357 | 0 | 391,357 | /s/ John Fucci | John Fucci, as Attorney-in-Fact for Aaron G.L. Fletcher | 0001789490 |
CIK / CUSIP context first